IL17A and neoplasm: In conjunction with the observation that IL-17A+ TILs are enriched in TNBC patients24,25,29, it is reasonable to speculate that IL-17A-induced anti-tumor immunity is a potential mechanism that works synergistically with neoadjuvant chemotherapy to achieve a favorable clinical response.